Geode Capital Management LLC Sells 5,585 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Geode Capital Management LLC trimmed its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 0.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,994,350 shares of the biopharmaceutical company’s stock after selling 5,585 shares during the period. Geode Capital Management LLC’s holdings in Dynavax Technologies were worth $38,246,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. E Fund Management Co. Ltd. lifted its position in Dynavax Technologies by 4.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 771 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC grew its position in Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 1,109 shares in the last quarter. GAMMA Investing LLC increased its stake in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the period. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 0.3 %

DVAX stock opened at $11.41 on Wednesday. The stock has a market capitalization of $1.42 billion, a PE ratio of 63.39 and a beta of 1.26. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $13.13 and a 200 day moving average of $12.58.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.